CTT Pharma Inc.
35 Galbraith Drive
Stoney Creek
Ontario
L8G 1Z7
Canada
Tel: 866-803-8386
Website: http://www.cttpharmaceuticals.com
Email: info@cttpharmaceuticals.com
About CTT Pharma Inc.
CTT’s principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the “Wafer”). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases including pain management.LEADERSHIP:
CEO: Brent Zettl
PRODUCTS:
All Products
4 articles about CTT Pharma Inc.
-
CTT Pharmaceuticals Existing Canadian Patent Confirmed to Include Psychedelic Applications
6/15/2021
CTT Pharmaceutical Holdings, Inc. announced today that Canadian law firm Gowlings WLC confirmed that CTT's Canadian patent CA2624110 covering Orally Administrable Wafers applies to all forms of Psychedelic applications.
-
CTT Enters into Business Development Partnership with 3 Rivers Biotech
9/8/2020
Partnership Further Advances Aggressive Business Development Strategy Pre-eminent Tissue Culture Company Provides Access to Substantial Network of CPG Companies 3 Rivers' Technology Transfer Capabilities Expand CTT's Operational Capacity HAMILTON, ON , Sept. 8, 2020 /PRNewswire/ - CTT Pharmaceutical Holdings, Inc., (the "Company" or "CTT")
-
CTT Pharma Files Statement of Claim against Aurora Cannabis and Appoints Dr. Shane Morris to Advisory Board
8/27/2020
CTT Pharmaceutical Holdings, Inc., (OTC: CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, today announced that its wholly owned Canadian subsidiary, CTT Pharma Inc. (the "Company" or "CTT"), has filed a statement of claim with the Ontario Superior Court of Justice aga
-
CTT Pharma Inc. And CTP Plasro Ltd Complete Exclusive Canadian Licensing Agreement For Cannabis Orally Dissolvable Thin Film (ODF) Wafer
2/17/2017